Although these novel biologic agents have shown promising results in many patients with asthma and COPD who have eosinophilic airway inflammation, it is evident that not all patients respond equally well, despite similar clinical, functional, and inflammatory characteristics. This heterogeneity in ...
Dupixent (dupilumab) is an interleukin-4 receptor alpha antagonist used for the treatment of atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, prurigo nodularis, and chronic obstructive pulmonary disease (COPD). Dupixent Approved in the US as the First-Ever...
Benralizumab, a monoclonal antibody, is already used for the long-term management of eosinophilic asthma, with studies still evaluating the effect of long-term management in eosinophilic COPD. However, the potential to manage critical moments, when symptoms suddenly worsen, had not been studied bef...
The therapeutic options can therefore be summarized as the 3 D’s: drugs, diet, and dilation [47]. Medical treatment of eosinophilic esophagitis Corticosteroids In the first study demonstrating that systemic corticosteroids are able to bring active EoE into remission, a series of pediatric patients ...
J. New Drugs for Asthma and COPD (Karger, Basel, 2001).This book reviews all of the new approaches to COPD therapy that are discussed in this review in more detail. Book Google Scholar Lancaster, T., Stead, L., Silagy, C. & Sowden, A. Effectiveness of interventions to help people...
(Fig. 6E). Among the top-ranking pathway, the RAGE pathway was regarded as the focus of attention, as RAGE signaling are involved in dendritic cell-T-cell cross-talk [46], and plays a central role in the pathogenesis of eosinophilic asthma [47]. The members of the NF-κB family are ...
"These are the patients that turn up in [the] emergency room with really bad asthma attacks and have the most morbidity from their disease," Dr Arron toldMedscape Medical News. "This is the target population for these new biologic therapies." The new therapies will cost more, but treat th...
The eosinophilic late-phase reaction, sometimes associated with the tissue damage that occurs in chronic idiopathic urticaria, is important in allergic responses. Cetirizine is a new H 1 antagonist with potent inhibitory action against the infiltration of eosinophils into involved tissue, thereby ...
Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma Frontiers in medicine, 4 (2017), p. 135, 10.3389/fmed.2017.00135 View in ScopusGoogle Scholar [80] J.M. FitzGerald, E.R. Bleecker, P. Nair, S. Korn, K. ...
half-life, tissue distribution and metabolism, spectrum of antihistaminic properties, and varying degrees of anti-inflammatory effects. With regard to the latter, there is growing awareness that some of these compounds might represent useful adjunct medications in asthma therapy. In terms of safety ...